Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05632757
Other study ID # RCAPHM22_0204
Secondary ID ID-RCB
Status Recruiting
Phase N/A
First received
Last updated
Start date June 22, 2023
Est. completion date June 22, 2025

Study information

Verified date January 2024
Source Assistance Publique Hopitaux De Marseille
Contact Annie Verschueren
Phone 0491386578
Email annie.verschueren@ap-hm.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes leads patients to a loss of hope and to dark thoughts. The prevalence of suicidal ideation is high, with more than one third of people with ALS experiencing it. The psychological suffering of patients is often associated with that of their caregivers. The evaluation of the patients' feeling of being a burden has rarely been addressed in previous studies in ALS on the notion of burden. In this work, the investigators wish to evaluate the patient's ideas of death by also taking into account the caregiver's burden and the patient's feeling of being a burden. They wish to better understand this difficult experience by refocusing the study on the patient himself, which has rarely been addressed in studies on ALS and the notion of burden. By working on the caregiver's burden, both from the caregiver's point of view and as perceived by the patient, the investigators hope to find avenues of intervention and define actions that could help patients and their families and improve the quality of life of the patient-caregiver couple.


Recruitment information / eligibility

Status Recruiting
Enrollment 126
Est. completion date June 22, 2025
Est. primary completion date December 22, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (patient) : - Patient is at least 18 years of age. - Patient having given informed consent - Patient with ALS who has already had at least two multidisciplinary assessments in the ALS center in Marseille with an evaluation by the clinical psychologist. - Patient with a motor handicap of grade 3 to 5 on the Rankin score - Patient with a primary family caregiver at home (spouse, child) willing to participate in the study - Patient who is a beneficiary of or affiliated with a social security plan Inclusion Criteria (caregiver) : - Adult subject at least 18 years of age. - Subject who has given informed consent. - Primary family caregiver of a patient with ALS who agrees to participate in the study - Caregiver present during hospital visits. Exclusion Criteria (patient): - Patients with a serious and unstable associated disease, cardiac, oncological, hepatic or renal, psychiatric (schizophrenia, bipolar) - Autonomous patient, who does not need the help of a third party for the basic gestures of daily life (Rankin 0 to 2) - Patient living in an institution or alone at home - Patient with cognitive impairment that interferes with activities of daily living - Patients with marked emotional lability (spasmodic crying) due to ALS - Patients who have had a recent diagnosis of their disease (less than 6 months) - Patients who are unaware of the severity of their condition - Any condition that in the opinion of the investigator or psychologist would not be compatible with the study. Exclusion Criteria (caregiver): - Subjects with severe and unstable cardiac, oncological, hepatic, renal or other illnesses. - Subject with a history of psychiatric illness

Study Design


Intervention

Behavioral:
Psychological assessments
The visit will take place during a multidisciplinary assessment in the ALS Center at the Timone Hospital, Neuromuscular Disease and ALS Department. The patient will be accompanied by his/her caregiver. During this multidisciplinary assessment, the patient is present at the hospital between 8am and 4pm. The various scales and self-questionnaires can be completed during this time. The time required to complete these scales and self-questionnaires is estimated to be about 90 minutes.

Locations

Country Name City State
France Service Maladies neuromusculaires et SLA Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact of the patient's sense of being a burden on the patient's suicidal ideation Columbia scale (highest score meaning better outcome) Inclusion visit (month 0)
Secondary Relationship between the patient's feeling of being a burden living Patient's Feelings of Burden Scale (highest score meaning worst outcome) Inclusion visit (month 0)
Secondary Relationship between the patient's reasons for living Patient Reasons for Living Scale (highest score meaning worst outcome) Inclusion visit (month 0)
Secondary Relationship between the patient's feeling of being a burden and the caregiver's feeling of hardship Patient's sense of burden scale and Zarit Caregiver Exertion Scale Inclusion visit (month 0)
Secondary Impact of the patient's sense of burden and the caregiver's sense of hardship on the quality of life of the patient and the caregiver WHOQOL-Bref (World Health Organization Quality of Life, highest score meaning better outcome) Inclusion visit (month 0)
Secondary Relationship between the patient's feeling of being a burden and the motor disability Beck scale (highest score meaning worse outcome) Inclusion visit (month 0)
Secondary Relationship between the patient's feeling of being a burden and the motor disability Rankin scale (highest score meaning worse outcome) Inclusion visit (month 0)
Secondary Relationship between the patient's feeling of being a burden and the motor disability ALSFRS score (highest score meaning better outcome) Inclusion visit (month 0)
Secondary Relationship between the depression of patient and the caregiver Beck scale (highest score meaning worse outcome) Inclusion visit (month 0)
Secondary Relationship between the depression of patient and the caregiver Rankin scale (highest score meaning worse outcome) Inclusion visit (month 0)
Secondary Relationship between the depression of patient and the caregiver ALSFRS score (highest score meaning better outcome) Inclusion visit (month 0)
Secondary Impact of the caregiver's feeling of hardship on the patient's reasons for living Patient Reasons for Living Scale (highest score meaning worst outcome) Inclusion visit (month 0)
Secondary Impact of the caregiver's feeling of hardship on the patient's reasons for living Columbia Scale (highest score meaning better outcome) Inclusion visit (month 0)
Secondary Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation Patient Reasons for Living Scale (highest score meaning worst outcome) Inclusion visit (month 0)
Secondary Impact of the caregiver's feeling of hardship on the patient's and suicidal ideation Columbia Scale (highest score meaning better outcome) Inclusion visit (month 0)
Secondary Relationship between the caregiver's perceived distress and the patient's suicidal ideation Zarit scale (highest score meaning worse outcome) Inclusion visit (month 0)
Secondary Relationship between the caregiver's perceived distress and the patient's suicidal ideation Columbia Scale (highest score meaning better outcome) Inclusion visit (month 0)
Secondary Relationship between caregiver's perceived distress and the patient's cognitive assessment ECAS score (Cognitif Edinburgh Cognitive and Behavioural ALS Screen) (highest score meaning better outcome) Inclusion visit (month 0)
See also
  Status Clinical Trial Phase
Terminated NCT04428775 - A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease Phase 2
Recruiting NCT04998305 - TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps Phase 1/Phase 2
Recruiting NCT05951556 - Telehealth Implementation of Brain-Computer Interface N/A
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND Phase 2/Phase 3
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Recruiting NCT04816227 - Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
Active, not recruiting NCT04494256 - A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation Phase 1/Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Recruiting NCT04882904 - Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. N/A
Completed NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA Phase 1
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT04220190 - RAPA-501 Therapy for ALS Phase 2/Phase 3
Not yet recruiting NCT06450691 - Modeling Amyotrophic Lateral Sclerosis With Fibroblasts N/A
Not yet recruiting NCT05860244 - Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients Phase 2
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A